Iconovo updates its long-term financial targets – expects strong revenue growth with a high margin


Iconovo expects to reach sales of SEK 250 million in 2027. The target for the operating profit in the same year is SEK 125 million, resulting in an operating margin of 50 percent. The company expects about one third of the revenue stream to come from Iconovo’s own pharmaceutical sales in the Nordic region through its subsidiary Iconovo Pharma. Iconovo’s future prospects and financial targets was described in more detail at a Capital Markets Day on June 1st and the presentations will soon be available on the company´s website.

Read the full press release here